Protara Therapeutics Ownership
| TARA Stock | USD 3.04 0.10 3.40% |
Shares in Circulation | First Issued 2014-09-30 | Previous Quarter 21.2 M | Current Value 22.3 M | Avarage Shares Outstanding 5.8 M | Quarterly Volatility 6.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Protara |
Protara Stock Ownership Analysis
About 51.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.77. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Protara Therapeutics recorded a loss per share of 2.64. The entity last dividend was issued on the 10th of January 2020. The firm had 1:40 split on the 10th of January 2020. Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. Protara Therapeutics, Inc. is headquartered in New York, New York. Artara Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people. To find out more about Protara Therapeutics contact the company at 646 844 0337 or learn more at https://www.protaratx.com.Besides selling stocks to institutional investors, Protara Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Protara Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Protara Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Protara Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Protara Therapeutics Insider Trades History
About 6.0% of Protara Therapeutics are currently held by insiders. Unlike Protara Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Protara Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Protara Therapeutics' insider trades
Protara Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Protara Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Protara Therapeutics backward and forwards among themselves. Protara Therapeutics' institutional investor refers to the entity that pools money to purchase Protara Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Oppenheimer & Co Inc | 2024-09-30 | 179.1 K | Geode Capital Management, Llc | 2024-09-30 | 170 K | Ikarian Capital, Llc | 2024-09-30 | 155.7 K | Blackrock Inc | 2024-06-30 | 115.3 K | Woodline Partners Lp | 2024-06-30 | 100 K | Two Sigma Advisers, Llc | 2024-06-30 | 80.5 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 77.4 K | Bridgeway Capital Management, Llc | 2024-09-30 | 49.2 K | Lpl Financial Corp | 2024-09-30 | 46 K | Ra Capital Management, Llc | 2024-09-30 | 1.9 M | Opaleye Management Inc | 2024-09-30 | 1.7 M |
Protara Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Protara Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Protara Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Protara Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Protara Therapeutics Outstanding Bonds
Protara Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Protara Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Protara bonds can be classified according to their maturity, which is the date when Protara Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| PL 1618 15 APR 26 Corp BondUS74368CBC73 | View | |
| US74368CAX20 Corp BondUS74368CAX20 | View | |
| US743674BE29 Corp BondUS743674BE29 | View | |
| US74368CAY03 Corp BondUS74368CAY03 | View | |
| PRXNA 3832 08 FEB 51 Corp BondUS74365PAE88 | View | |
| PL 5366 06 JAN 26 Corp BondUS74368CBQ69 | View | |
| PRXNA 4027 03 AUG 50 Corp BondUS74365PAD06 | View | |
| PRXNA 3257 19 JAN 27 Corp BondUS74365PAG37 | View |
Protara Therapeutics Corporate Filings
13A | 18th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 12th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Protara Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protara Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protara Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protara Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Return On Assets (0.28) | Return On Equity (0.46) |
The market value of Protara Therapeutics is measured differently than its book value, which is the value of Protara that is recorded on the company's balance sheet. Investors also form their own opinion of Protara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protara Therapeutics' market value can be influenced by many factors that don't directly affect Protara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.